BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 22919028)

  • 1. Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome.
    Matsuura S; Komeno Y; Stevenson KE; Biggs JR; Lam K; Tang T; Lo MC; Cong X; Yan M; Neuberg DS; Zhang DE
    Blood; 2012 Nov; 120(19):4028-37. PubMed ID: 22919028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
    Harada Y; Harada H
    J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.
    Satoh Y; Matsumura I; Tanaka H; Harada H; Harada Y; Matsui K; Shibata M; Mizuki M; Kanakura Y
    Leukemia; 2012 Feb; 26(2):303-11. PubMed ID: 21836608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Runx1 downregulates stem cell and megakaryocytic transcription programs that support niche interactions.
    Behrens K; Triviai I; Schwieger M; Tekin N; Alawi M; Spohn M; Indenbirken D; Ziegler M; Müller U; Alexander WS; Stocking C
    Blood; 2016 Jun; 127(26):3369-81. PubMed ID: 27076172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
    Matsumura T; Nakamura-Ishizu A; Muddineni SSNA; Tan DQ; Wang CQ; Tokunaga K; Tirado-Magallanes R; Sian S; Benoukraf T; Okuda T; Asou N; Matsuoka M; Osato M; Suda T
    Blood; 2020 Oct; 136(17):1919-1932. PubMed ID: 32573733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
    Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
    Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
    Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
    Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
    Harada H; Harada Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome.
    Yokomizo-Nakano T; Kubota S; Bai J; Hamashima A; Morii M; Sun Y; Katagiri S; Iimori M; Kanai A; Tanaka D; Oshima M; Harada Y; Ohyashiki K; Iwama A; Harada H; Osato M; Sashida G
    Cancer Res; 2020 Jun; 80(12):2523-2536. PubMed ID: 32341038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
    Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
    Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ectopic Runx1 expression rescues Tal-1-deficiency in the generation of primitive and definitive hematopoiesis.
    Tornack J; Seiler K; Grützkau A; Grün JR; Onodera M; Melchers F; Tsuneto M
    PLoS One; 2013; 8(7):e70116. PubMed ID: 23922928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for RUNX1 in hematopoiesis and myeloid leukemia.
    Ichikawa M; Yoshimi A; Nakagawa M; Nishimoto N; Watanabe-Okochi N; Kurokawa M
    Int J Hematol; 2013 Jun; 97(6):726-34. PubMed ID: 23613270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
    Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
    Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
    Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
    Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
    Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
    Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
    Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
    Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
    Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
    Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
    Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.